Candidate diagnostic biomarkers for neurodevelopmental disorders in children and adolescents: a systematic review
- PMID: 36640395
- PMCID: PMC9840506
- DOI: 10.1002/wps.21037
Candidate diagnostic biomarkers for neurodevelopmental disorders in children and adolescents: a systematic review
Abstract
Neurodevelopmental disorders - including attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder, communication disorders, intellectual disability, motor disorders, specific learning disorders, and tic disorders - manifest themselves early in development. Valid, reliable and broadly usable biomarkers supporting a timely diagnosis of these disorders would be highly relevant from a clinical and public health standpoint. We conducted the first systematic review of studies on candidate diagnostic biomarkers for these disorders in children and adolescents. We searched Medline and Embase + Embase Classic with terms relating to biomarkers until April 6, 2022, and conducted additional targeted searches for genome-wide association studies (GWAS) and neuroimaging or neurophysiological studies carried out by international consortia. We considered a candidate biomarker as promising if it was reported in at least two independent studies providing evidence of sensitivity and specificity of at least 80%. After screening 10,625 references, we retained 780 studies (374 biochemical, 203 neuroimaging, 133 neurophysiological and 65 neuropsychological studies, and five GWAS), including a total of approximately 120,000 cases and 176,000 controls. While the majority of the studies focused simply on associations, we could not find any biomarker for which there was evidence - from two or more studies from independent research groups, with results going into the same direction - of specificity and sensitivity of at least 80%. Other important metrics to assess the validity of a candidate biomarker, such as positive predictive value and negative predictive value, were infrequently reported. Limitations of the currently available studies include mostly small sample size, heterogeneous approaches and candidate biomarker targets, undue focus on single instead of joint biomarker signatures, and incomplete accounting for potential confounding factors. Future multivariable and multi-level approaches may be best suited to find valid candidate biomarkers, which will then need to be validated in external, independent samples and then, importantly, tested in terms of feasibility and cost-effectiveness, before they can be implemented in daily clinical practice.
Keywords: ADHD; Biological markers; autism spectrum disorder; communication disorders; genome-wide association studies; intellectual disability; motor disorders; neurodevelopmental disorders; neuroimaging; neurophysiology; specific learning disorders; tic disorders.
© 2023 World Psychiatric Association.
Figures
Similar articles
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
-
A state-of-the-art overview of candidate diagnostic biomarkers for Attention-deficit/hyperactivity disorder (ADHD).Expert Rev Mol Diagn. 2024 Apr;24(4):259-271. doi: 10.1080/14737159.2024.2333277. Epub 2024 Mar 26. Expert Rev Mol Diagn. 2024. PMID: 38506617
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
The cost-effectiveness of treatments for attention deficit-hyperactivity disorder and autism spectrum disorder in children and adolescents: a systematic review.Eur Child Adolesc Psychiatry. 2022 Nov;31(11):1655-1670. doi: 10.1007/s00787-021-01748-z. Epub 2021 Mar 9. Eur Child Adolesc Psychiatry. 2022. PMID: 33751229 Free PMC article. Review.
-
Omega-3 fatty acids from Supplements Consumed before and during Pregnancy and Lactation and Developmental Milestones, Including Neurocognitive Development, in the Child: A Systematic Review [Internet].Alexandria (VA): USDA Nutrition Evidence Systematic Review; 2020 Jul. Alexandria (VA): USDA Nutrition Evidence Systematic Review; 2020 Jul. PMID: 35289988 Free Books & Documents. Review.
Cited by
-
A new approach towards highly sensitive detection of endogenous N-acetylaspartic acid, N-acetylglutamic acid, and N-acetylaspartylglutamic acid in brain tissues based on strong anion exchange monolith microextraction coupled with UHPLC-MS/MS.Mikrochim Acta. 2024 May 31;191(6):360. doi: 10.1007/s00604-024-06431-z. Mikrochim Acta. 2024. PMID: 38819644
-
The copy number variant architecture of psychopathology and cognitive development in the ABCD® study.medRxiv [Preprint]. 2024 May 15:2024.05.14.24307376. doi: 10.1101/2024.05.14.24307376. medRxiv. 2024. PMID: 38798629 Free PMC article. Preprint.
-
Individualized prediction models in ADHD: a systematic review and meta-regression.Mol Psychiatry. 2024 May 23. doi: 10.1038/s41380-024-02606-5. Online ahead of print. Mol Psychiatry. 2024. PMID: 38783054
-
A Thalamocortical Perspective on Sleep Spindle Alterations in Neurodevelopmental Disorders.Curr Sleep Med Rep. 2024;10(2):103-118. doi: 10.1007/s40675-024-00284-x. Epub 2024 Mar 11. Curr Sleep Med Rep. 2024. PMID: 38764858 Free PMC article. Review.
-
Des-Arg(9) bradykinin as a causal metabolite for autism spectrum disorder.World J Psychiatry. 2024 Jan 19;14(1):88-101. doi: 10.5498/wjp.v14.i1.88. eCollection 2024 Jan 19. World J Psychiatry. 2024. PMID: 38327885 Free PMC article.
References
-
- FDA‐NIH Biomarker Working Group . BEST (Biomarkers, EndpointS, and other Tools) resource. Bethesda: National Institutes of Health, 2016. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous